A Phase 4 interventional study of Pitavastatin and Pitavastatin in Percutaneous Coronary Intervention, sponsored by JW Pharmaceutical. Withdrawn at 1 site in Korea, Republic of. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-03-30.
Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Prevention
Patients who is scheduled elective PCI are randomized to pitavastatin 4mg daily or without pitavastatin for 5 -7days before the procedure. Creatine kinase-MB, troponin I, and myoglobin levels are measured at baseline and at 8 and 24 hours after the procedure(1st evaluation). After PCI, pitavastatin will be administered for additional 4 weeks(2nd evaluation).
Procedural ischemic myocardial injury remains the most frequent complication after coronary angioplasty. Recently it was reported that pretreatment with atorvastatin reduce the myocardial damage compared to placebo. Thus, we will evaluate the difference of pretreatment of pitavastatin compared to standard therapy on the reduction of myocardial damage in patient who is scheduled elective PCI for stable angina pectoris.
519 studies on the registry are indexed under Angina Pectoris; 82 are open to participants now.
Browse Angina Pectoris studies →JW Pharmaceutical is the lead sponsor of 75 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Pitavastatin
Drug: Pitavastatin
4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
4mg daily for 28 days after PCI
Proportion of patients whose CK-MB > 2 times above UNL
Time frame: First evaulation time (before PCI)
Proportion of patients who show any increase of CK-MB, troponin I, and myoglobin above UNL
Time frame: First evaluation time
Mean peak values of CK-MB, troponin I and myoglobin after intervention
Time frame: After PCI (<24hrs)
Change of hs-CRP, wall motion score
Time frame: Second evaluation time
Occurence of all major adverse cardiac events
Time frame: Second evaluation time
This study is withdrawn, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JW Pharmaceutical